D. Baumgart and W. Sandborn, Crohn's disease, The Lancet, vol.380, issue.9853, pp.1590-605, 2012.
DOI : 10.1016/S0140-6736(12)60026-9

M. Olesen, C. Coskun, M. Peyrin-biroulet, L. Nielsen, and O. H. , Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases, Pharmacology & Therapeutics, vol.159, pp.110-119, 2016.
DOI : 10.1016/j.pharmthera.2016.01.001

M. Van-der-have, K. S. Van-der-aalst, K. A. Leenders, M. , S. P. Oldenburg et al., Determinants of health-related quality of life in Crohn's disease: A systematic review and meta-analysis, Journal of Crohn's and Colitis, vol.8, issue.2, pp.93-106, 2014.
DOI : 10.1016/j.crohns.2013.04.007

L. Peyrin-biroulet, E. Loftus, . Jr, J. Colombel, and W. Sandborn, The Natural History of Adult Crohn's Disease in Population-Based Cohorts, The American Journal of Gastroenterology, vol.132, issue.2, pp.289-97, 2010.
DOI : 10.1053/j.gastro.2008.09.053

P. Kawalec and K. P. Malinowski, Indirect health costs in ulcerative colitis and Crohn???s disease: a systematic review and meta-analysis, Expert Review of Pharmacoeconomics & Outcomes Research, vol.24, issue.2, pp.253-266, 2015.
DOI : 10.3748/wjg.14.6641

N. Molodecky, I. Soon, D. Rabi, W. Ghali, M. Ferris et al., Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review, Gastroenterology, vol.142, issue.1, pp.46-54, 2012.
DOI : 10.1053/j.gastro.2011.10.001

G. Assche, J. Axler, H. Kim, S. Danese, I. Fox et al., GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for Ulcerative Colitis, N Engl J Med, vol.369, issue.8, pp.699-710, 2013.

W. Sandborn, B. Feagan, P. Rutgeerts, S. Hanauer, J. Colombel et al., GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease, N Engl J Med, vol.22, issue.8, pp.369711-369732, 2013.

B. Sands, B. Feagan, P. Rutgeerts, J. Colombel, W. Sandborn et al., Effects of Vedolizumab Induction Therapy for Patients With Crohn???s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed, Gastroenterology, vol.147, issue.3, pp.618-627, 2014.
DOI : 10.1053/j.gastro.2014.05.008

P. Dulai, S. Singh, X. Jiang, F. Peerani, N. Narula et al., The Real-World Effectiveness and Safety of Vedolizumab for Moderate???Severe Crohn???s Disease: Results From the US VICTORY Consortium, The American Journal of Gastroenterology, vol.4, issue.8, pp.1147-55, 2016.
DOI : 10.1016/j.crohns.2010.05.011

A. Amiot, J. Grimaud, L. Peyrin-biroulet, J. Filippi, B. Pariente et al., Effectiveness and Safety of Vedolizumab Induction Therapy for??Patients With Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.14, issue.11, pp.1593-1601, 2016.
DOI : 10.1016/j.cgh.2016.02.016

URL : https://hal.archives-ouvertes.fr/hal-01278611

N. Williet, G. Boschetti, M. Fovet, D. Bernado, T. Claudez et al., Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months, Clinical Gastroenterology and Hepatology, vol.15, issue.11, pp.1542-356531121, 2016.
DOI : 10.1016/j.cgh.2016.11.023

M. Rosario, N. Dirks, M. Gastonguay, A. Fasanmade, T. Wyant et al., Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease, Alimentary Pharmacology & Therapeutics, vol.41, issue.Suppl. 1, pp.188-202, 2015.
DOI : 10.1002/jcph.240

A. Al-darmaki, J. Hubbard, C. Seow, Y. Leung, K. Novak et al., Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis, Inflammatory Bowel Diseases, vol.23, issue.8, pp.1272-1277, 2017.
DOI : 10.1097/MIB.0000000000001211

D. Laharie, M. Salzmann, H. Boubekeur, R. F. Amouretti, M. Quinton et al., Predictors of response to infliximab in luminal Crohn's disease, Gastroent??rologie Clinique et Biologique, vol.29, issue.2, pp.145-154, 2005.
DOI : 10.1016/S0399-8320(05)80718-3

S. Vermeire, E. Louis, A. Carbonez, G. Van-assche, M. Noman et al., Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease, The American Journal of Gastroenterology, vol.35, issue.9, pp.2357-63, 2002.
DOI : 10.1046/j.1365-2567.2000.00079.x

I. Arnott, G. Mcneill, and J. Satsangi, An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.117, issue.12, pp.1451-1458, 200315.
DOI : 10.1111/j.1572-0241.2002.05784.x

S. Subramanian, A. Ekbom, and J. Rhodes, Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?, Gut, vol.257, issue.(1), pp.362-381, 2017.
DOI : 10.1097/SLA.0b013e31827d99a2

I. Cleynen, J. González, C. Figueroa, A. Franke, D. Mcgovern et al., Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project, Gut, vol.58, issue.Suppl 04, pp.1556-65, 2013.
DOI : 10.1136/gut.2007.144865

B. Christensen, S. Goeppinger, R. Colman, D. Siddiqui, A. Yarur et al., Tu1350 Vedolizumab in the Treatment of IBD: The University of Chicago Experience, Gastroenterology, vol.148, issue.4, p.866, 2015.
DOI : 10.1016/S0016-5085(15)32937-1

J. Satsangi, M. Silverberg, S. Vermeire, and J. Colombel, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006.
DOI : 10.1136/gut.2005.082909

R. Harvey and J. Bradshaw, A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY, The Lancet, vol.315, issue.8167, p.514, 1980.
DOI : 10.1016/S0140-6736(80)92767-1

L. Peyrin-biroulet, J. Panés, W. Sandborn, S. Vermeire, S. Danese et al., Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions, Clinical Gastroenterology and Hepatology, vol.14, issue.3, pp.348-354, 2016.
DOI : 10.1016/j.cgh.2015.06.001

L. Peyrin-biroulet, W. Sandborn, B. E. Sands, W. Reinisch, W. Bemelman et al., Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, The American Journal of Gastroenterology, vol.107, issue.9, pp.1324-1338, 2015.
DOI : 10.1038/ajg.2012.117

URL : https://hal.archives-ouvertes.fr/hal-01191653

O. Adedokun, W. Sandborn, B. Feagan, P. Rutgeerts, Z. Xu et al., Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis, Gastroenterology, vol.147, issue.6, pp.1296-1307, 2014.
DOI : 10.1053/j.gastro.2014.08.035

P. Rutgeerts, W. Sandborn, B. Feagan, W. Reinisch, A. Olson et al., Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.353, issue.23, pp.2462-2476, 2005.
DOI : 10.1056/NEJMoa050516

S. Vermeire, S. Schreibe, and W. Sandborn, Correlation Between the Crohn's Disease Activity and Harvey???Bradshaw Indices in Assessing Crohn's Disease Severity, Clinical Gastroenterology and Hepatology, vol.8, issue.4, pp.357-63, 2010.
DOI : 10.1016/j.cgh.2010.01.001

J. Satsangi, M. Silverberg, S. Vermeire, and J. Colombel, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006.
DOI : 10.1136/gut.2005.082909

L. Peyrin-biroulet, Y. Bouhnik, X. Roblin, G. Bonnaud, and H. Hagège, French national consensus clinical guidelines for the management of Crohn???s disease, Digestive and Liver Disease, vol.49, issue.4, pp.368-377, 2017.
DOI : 10.1016/j.dld.2016.12.008

A. Amiot, M. Serrero, L. Peyrin-biroulet, J. Filippi, B. Pariente et al., One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study, Alimentary Pharmacology & Therapeutics, vol.66, issue.618-627, pp.310-321, 2017.
DOI : 10.1136/gutjnl-2015-311079

B. Sands, B. Feagan, P. Rutgeerts, J. Colombel, W. Sandborn et al., Effects of Vedolizumab Induction Therapy for Patients With Crohn???s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed, Gastroenterology, vol.147, issue.3, pp.618-627, 2014.
DOI : 10.1053/j.gastro.2014.05.008

G. Pineton-de-chambrun, L. Peyrin-biroulet, M. Lémann, and J. Colombel, Clinical implications of mucosal healing for the management of IBD, Nature Reviews Gastroenterology & Hepatology, vol.50, issue.1, pp.15-29, 2010.
DOI : 10.1111/j.1572-0241.2005.41992.x

D. Baumgart, B. Bokemeyer, A. Drabik, A. Stallmach, S. Schreiber et al., Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study, Alimentary Pharmacology & Therapeutics, vol.60, issue.Suppl. A, pp.1090-102, 2016.
DOI : 10.1136/gut.2010.226548

E. Shelton, J. Allegretti, B. Stevens, M. Lucci, H. Khalili et al., Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients, Inflammatory Bowel Diseases, vol.21, issue.12, pp.2879-85, 2015.
DOI : 10.1097/MIB.0000000000000561

U. Kopylov, Y. Ron, I. Avni-biron, B. Koslowsky, M. Waterman et al., Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease???the Israeli Real-World Experience, Inflammatory Bowel Diseases, vol.23, issue.3, pp.404-408, 2017.
DOI : 10.1097/MIB.0000000000001039

M. Samaan, P. Pavlidis, E. Johnston, B. Warner, J. Digby-bell et al., Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres, Frontline Gastroenterology, vol.110, issue.3, pp.196-202, 2017.
DOI : 10.1136/flgastro-2016-100720

S. Zundler, A. Fischer, D. Schillinger, M. Binder, R. Atreya et al., The ??4??1 Homing Pathway is Essential for Ileal Homing of Crohn's Disease Effector T Cells in vivo, Gastroenterology, vol.152, issue.5, pp.379-391, 2017.
DOI : 10.1016/S0016-5085(17)30841-7

A. Ananthakrishnan, C. Luo, V. Yajnik, H. Khalili, J. Garber et al., Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases, Cell Host & Microbe, vol.21, issue.5, pp.603-610, 2017.
DOI : 10.1016/j.chom.2017.04.010

A. Stallmach, C. Langbein, R. Atreya, T. Bruns, A. Dignass et al., Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study, Alimentary Pharmacology & Therapeutics, vol.21, issue.Suppl. 1, pp.11-121199, 2016.
DOI : 10.1097/MIB.0000000000000273

J. Colombel, W. Sandborn, and W. Reinisch, Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-1395, 2010.
DOI : 10.1056/NEJMoa0904492

R. Panaccione, S. Ghosh, S. Middleton, J. Márquez, B. Scott et al., Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis, Gastroenterology, vol.146, issue.2, pp.392-400, 2014.
DOI : 10.1053/j.gastro.2013.10.052

J. Jones, G. Kaplan, L. Peyrin-biroulet, L. Baidoo, S. Devlin et al., Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti???Tumor Necrosis Factor Therapy for Crohn???s Disease: A Meta-analysis of Placebo-controlled Trials, Clinical Gastroenterology and Hepatology, vol.13, issue.13, pp.2233-2273, 2015.
DOI : 10.1016/j.cgh.2015.06.034

J. Allegretti, E. Barnes, B. Stevens, M. Storm, A. Ananthakrishnan et al., Predictors of Clinical Response and Remission at 1??Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab, Digestive Diseases and Sciences, vol.15, issue.6, pp.1590-1596, 2017.
DOI : 10.1002/ibd.20918

C. Ha, T. Ullman, C. Siegel, and A. Kornbluth, Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population, Clinical Gastroenterology and Hepatology, vol.10, issue.9, pp.1002-1009, 2012.
DOI : 10.1016/j.cgh.2012.02.004